Clinical Trials Browser

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05990231 2023-09-11

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Phase 2 Unknown

35 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Esophageal Squamous Cell Carcinoma

NCT05915481 2023-06-23

SCARCE

Phase 1/2 Unknown

60 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04631731 2023-06-01

ICEMELT

Phase 1/2 Unknown

200 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicOther solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Stomach Neoplasms, Endometrial Neoplasms

NCT05235438 2023-05-24

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Phase 1 Unknown

16 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Phase 1 Terminated

6 enrolled 11 charts

Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

NCT03354962 2020-12-04

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Phase 1/2 Terminated

6 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT03356782 2020-06-11

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Phase 1/2 Unknown

20 enrolled

Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Bone Neoplasms, Sarcoma, Sarcoma, Ewing

NCT01896869 2020-05-19

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Phase 2 Completed

83 enrolled 16 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Pancreatic Neoplasms

NCT00836407 2020-02-24

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Phase 1 Completed

30 enrolled 9 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Pancreatic Neoplasms

NCT03549546 2019-07-26

POIR

Phase NA Completed

31 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lung Neoplasms, Lymphopenia

NCT03182803 2017-06-09

CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor

Phase 1/2 Unknown

40 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

NCT03182816 2017-06-09

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Phase 1/2 Unknown

40 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

NCT03179007 2017-06-07

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Phase 1/2 Unknown

40 enrolled

Diabetes Mellitus, Insulin-Dependent, 12

NCT01331525 2016-04-14

ICE

Phase 2 Completed

42 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Small Cell Lung Carcinoma

NCT01216436 2015-05-25

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

Phase 1 Terminated

2 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT00028431 2014-05-22

Novel Adjuvants for Peptide-Based Melanoma Vaccines

Phase 1 Completed

19 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

Clinical Trials

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

NEST-1

ENZYMELA

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

IMMUNO-FIT Observational Study

TICIMEL

PHOENIX

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

MIRAE

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

NEXIS

A Phase II Study of CRT Combined With QL1706 in ESCC Patients

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

SCARCE

ICEMELT

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

POIR

CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

ICE

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

Novel Adjuvants for Peptide-Based Melanoma Vaccines